Kymera Therapeutics Inc. has described salts of IL-1 receptor-associated kinase 4 (IRAK-4) degradation inducers and their crystalline forms reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Scientists at Centre Hospitalier Regional Universitaire de Lille, INSERM and University of Lille have divulged diphenylpyrazole compounds acting as β-amyloid (Aβ) production inhibitors and autophagy marker ratio modulators reported to be useful for the treatment of Alzheimer’s disease.
Sanwa Kagaku Kenkyusho Co. Ltd. has synthesized imidazole derivatives acting as α1A-adrenoceptor agonists reported to be useful for the treatment of orthostatic hypotension and urinary incontinence.
Appicine Therapeutics (HK) Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers at Biodol Therapeutics SAS, Centre National de la Recherche Scientifique, INSERM and Université de Strasbourg have divulged new n-heteroarylbenzamide derivatives acting as FLT3 (FLK2/STK1) inhibitors and reported to be useful for the treatment of pain.
Hanmi Holdings Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.